Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07895524
PHASE2

A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. Researchers are doing this trial to learn if a trial medicine called MK-8690 can treat symptoms of active RA in people who are taking MTX. The goal of this study is to learn if MK-8690 works better than placebo to improve RA symptoms.

Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-11-23

Completion Date

2028-11-28

Last Updated

2026-10-26

Healthy Volunteers

No

Interventions

COMBINATION_PRODUCT

MK-8690

Solution for SC injection

COMBINATION_PRODUCT

Placebo

Solution for SC injection

DRUG

Methotrexate (MTX)

Background therapy - variable dose strength with route of administration per approved product label